Cellceutix continues to gain industry attention by both investors, big pharma and publications. Their Chief Executive Officer was featured on the front page of Friday's Boston Business Journal. As the clinical trials for Kevetrin should be starting in a couple months at Dana-Farber, attention should continue to increase. The press notes that shares have gained a lot more liquidity in the last year, not to mention share value 150 percent higher than this time in January 2011.

Read the complete press at the link provided.

------------------------------------

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated on several occasions for news dissemination and journalism services from Cellceutix Corporation and holds a total of 100,000 shares of 144 restricted stock of Cellceutix Corporation, none of which has been sold to date, nor intends to be sold in the near term. Prior compensation is listed in our full disclosure. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.